More

    DCGI approval for Bharat Biotech’s nasal booster dose trials

    HealthCOVID-19DCGI approval for Bharat Biotech’s nasal booster dose trials
    - Advertisment -

    DCGI approval for Bharat Biotech’s nasal booster dose trials

    The producer of India’s indigenous vaccine, Covaxin, will now be able to conduct trials of its nasal vaccine as a booster dose at nine locations in the country.

    The Drug Controller General of India today gave its approval to Indian biotechnology-pharma company, Bharat Biotech, to conduct Phase-III clinical trials of a nasal vaccine it has developed. The trials of the intranasal booster dose will be conducted on people who have received both doses of Bharat Biotech’s Covaxin.

    Covaxin producer will now be able to conduct trials of its nasal vaccine as a booster dose at nine locations in the country.

    An intranasal vaccine has logistical advantages and will be easier to administer in mass vaccination drives. The company claims that the BBV154 vaccine stimulates a broad immune response, especially at the site of infection (in the nasal mucosa that lines the nasal cavity) – essential for blocking both infection and transmission of COVID-19.

    - Advertisement -

    Besides ease of administration – as it does not require trained health care workers, the nasal vaccine also eliminates risks of injuries and infections that might be associated with a needle administered jab. It can elicit a high degree of compliance, especially as it suits children and adults.

    The non-invasive and needle-free nasal route has excellent potential for vaccination due to the organised immune systems of the nasal mucosa.

    Biotechnology feat

    The biotechnology company has applied to the Drug Controller General of India for approval for phase-III trials of the BBV154 vaccine in December 2021.

    If given the green signal following the trials, Bharat Biotech claims it will be able to undertake large-scale to meet global demands.

    The attenuated avirulant vaccine comes from a modified chimpanzee adenovirus. (This is a harmless, weakened adenovirus that usually causes the common cold in chimpanzees.) In this respect, the operative biologicals of this vaccine are somewhat like the AstraZeneca vaccine that also uses a chimpanzee adenovirus vaccine vector that has been genetically changed to stop it from adversely affecting humans.

    According to the company, mice, hamsters and macaques immunized with a single dose of the vaccine “conferred superior protection against SARS-CoV-2 challenge”.

    It claims that intranasal immunization “can create an immune response in the nose, which is the point of entry for the virus—thereby protecting against disease, infection, and transmission.”

    - Advertisement -

    LEAVE A REPLY

    Please enter your comment!
    Please enter your name here

    Latest news

    War, huh, Yeah, What is it Good For?

    One should, nevertheless, keep in mind that war is horrific. It is most often not the answer. When it is, it is always the very last resort after all other means to resolve adverse situations have been well and truly exhausted.

    World Bank Unveils $1 Billion Package to Spur Jobs and Private Sector Growth in Sri Lanka

    Tourism, one of Sri Lanka’s key economic drivers, is set to receive $200 million. These funds will be used to protect and enhance natural and cultural heritage sites, create employment opportunities, and ensure local communities benefit directly from tourism revenues.

    UN Secretary-General Urges Military restraint from India, Pakistan

    He offered his good offices to both governments to help defuse tensions and promote diplomacy, stressing that “a military solution is no solution.”

    India Showcases SVAMITVA at World Bank Land Conference

    India’s interventions across these sessions aim to serve as a call to action for other nations striving to achieve SDG Target 1.4.2 which aims to ensure legal ownership and control over land for all, especially vulnerable communities.
    - Advertisement -

    WHO Warns of Deepening Health Crisis in Afghanistan as Aid Dwindles

    The decline in support follows the suspension of US assistance, which previously accounted for nearly half of the international funding directed toward Afghanistan’s healthcare.

    Clean Ganga Mission Approves Key Projects for Ganga Rejuvenation via Ecosystem Testoration

    Conservation of critical wetlands and promoting the reuse of treated wastewater through city specific reuse plans and were deliberated in the meeting.

    Must read

    War, huh, Yeah, What is it Good For?

    One should, nevertheless, keep in mind that war is horrific. It is most often not the answer. When it is, it is always the very last resort after all other means to resolve adverse situations have been well and truly exhausted.

    World Bank Unveils $1 Billion Package to Spur Jobs and Private Sector Growth in Sri Lanka

    Tourism, one of Sri Lanka’s key economic drivers, is set to receive $200 million. These funds will be used to protect and enhance natural and cultural heritage sites, create employment opportunities, and ensure local communities benefit directly from tourism revenues.
    - Advertisement -

    More from the sectionRELATED
    Recommended to you